Belluscura

BELLHealthcare
0.7650GBX
5.52%
Market Cap
3.39M
Volume
281.99k
6% of avg
P/E Ratio
EPS (TTM)
0
Beta
0.71
Day Range
0.7100p - 0.7650p
52 Week Range
0.4950p0.7650p18.0000p
0.7650p

Upcoming Events

Q3 2025
Full commercial launch of the DISCOV-R product
High Impact Event
BELL
NEUTRAL

Belluscura Plc Announces Holding(s) in Company Change

The healthcare company has announced a change in its major shareholding.

BELL
NEUTRAL

Belluscura Plc Announces Director Dealings

The healthcare company has announced changes to its major shareholdings.

BELL
NEUTRAL

Belluscura Provides Update on Recent Share Price Movement

The medical device company issues a statement addressing recent fluctuations in its share price, with no new updates on its business performance or outlook.

BELL
NEUTRAL

Belluscura Initiates Strategic Review to Address Funding Needs

The medical device company is launching a strategic review to address its funding needs, as it faces product sourcing challenges and seeks to strengthen its capital position.

BELL
GOOD

Belluscura Reports Strong Q1 Sales, Launches New Portable Oxygen Concentrator

The medical device developer reports a substantial increase in Q1 sales and the launch of a new portable oxygen concentrator, despite some tariff-related challenges.

BELL
NEUTRAL

Belluscura Announces Director Shareholding Change

The healthcare company has announced a change in director shareholding.

BELL
NEUTRAL

Belluscura Announces Change in Shareholding

The healthcare company has announced a change in its shareholding structure.

BELL
NEUTRAL

Belluscura Announces Change in Major Shareholding

The medical device company reports a change in major shareholding, with no significant implications.

BELL
NEUTRAL

Belluscura Announces Change in Major Shareholding

The medical device company has announced a change in major shareholding, with Dowgate Group Limited reducing its stake in the business.

BELL
NEUTRAL

Belluscura Announces Director Dealing

The medical device company has announced a change in major shareholding, with a director reducing their stake.